In Leander's concept, $1 million buys a 10% share, which is prepared for drugs that have passed the first phase of clinical trials.

The first phase of clinical trial is a safety test, which is prepared to test whether the drug has strong side effects.

Through this project, it is not difficult, if you take a few milligrams a day, Guanyin soil can also pass the first phase of clinical testing.

Therefore, a drug that can really get a valuation of $10 million after the first phase of clinical trials must be famous and promising.

Just like now, if Yang Rui or his laboratory makes a certain compound and passes the first phase of clinical experiments, it will naturally deserve a valuation of tens of millions.

However, Yang Rui is now empty-handed.

It is equivalent to saying that he used his name in exchange for a valuation of tens of millions of dollars.

That's $10 million in 1986, and it's worth a lot of money. Moreover, although there was some bubble in the biomedical industry in the 80s, it could not be compared with the Internet industry after all, and there were only a few pharmaceutical companies that could come up with a lot of money, relatively speaking, they were still conservative.

The $15 million valuation offered by Greenstone Corner has washed away Leander's perception.

To say that pharmaceutical companies occasionally produce one or two fools, just like real estate developers, there are always heads pumped and holding up a sign to buy a piece of rotten land, but the probability of two fools meeting together at the same time is still relatively small.

Leander looked at the manager of Greenstone Corner on the left, and then at the manager of GlaSmithKline on the right, and couldn't help but wonder.

"$1.7 million, ten percent. "GlensmithKline's Thorndike has made another offer.

Hawthorn of Greenstone Corner called out $1.8 million and looked at Thorndik.

Leander is familiar with this kind of look, that is the look that you shout high, and I will quit.

Leander's attention was on Thorndike's face.

Thorndike smiled smugly and said steadily, "$1.85 million, ten percent." ”

He didn't need to charge a higher price, and Hawthorn of Greenstone Point had to save a little for the company if he was to quit.

Hawthorn's expression was a little distorted, and he hesitated for a few seconds, before Yang Rui was about to speak, and said, "$1.5 million, eight percent." ”

At first glance, it may sound like he was lowering the number, but because the proportion was smaller, the actual valuation was a little higher, to $18.75 million, although it was only $250,000 more than Thorndike's Gramsk, which made the latter even more entangled.

Leander suddenly realized that the two companies were actually competing for the right to participate.

Ten or eight percent of the equity is just a barrier to entry for them, and what a company really spends is only more than a million dollars.

Even by the standard of 86 years, more than one million dollars is not a very large number for pharmaceutical companies, whether it is for marketing or research investment, this is less than a month's expenditure.

However, Leander did not get the relevant authorization from the company, which made him a little anxious.

Fortunately, Yang Rui quickly stopped the circular price of Greenstone Corner and GlaSmithKline, waved his hand, and said: "One thing you may not know is that the new drug I made is going to be put into production in China. ”

"Huh, is it made in China?" Thorndike sat up straight.

Hawthorn and Leander also showed expressions of concern. However, compared with GramSmithKline, Greenstone Corner and Kaliz Pharmaceuticals are both small and medium-sized enterprises, and they have less high requirements for the source of drugs.

Not so much at GlensmithKline. Whether they are world-class multinationals, there is still a difference in sales between drugs made in the United States and drugs produced in China.

Of course, it is not completely impossible, for example, India has been producing all kinds of drugs for European and American pharmaceutical companies for a long time, and its chemical industry was once quite prosperous.

Yang Rui didn't care what several companies thought, smiled and said: "I have two suggestions, one is to build a joint venture factory, and everyone shares the benefits of the production part." If you don't want to, you can also act as an agent for sales, but this priority is lower than that of the partners of the joint venture factory, and only if the joint venture party gives up the sale, it will be handed over to other companies. ”

Several white men looked at each other again.

"Professor Yang, Gaucher disease is a rare disease, and there are only a few hundred thousand patients in the world, so if you establish a joint venture factory, the profit in terms of production will be very low. Hawthorn and the white man who came with him flowed for a few seconds, and then asked.

"No, it won't. Yang Rui said: "We have a new idea in terms of enzyme substitution, and if it can be realized, it needs a larger factory to accommodate it." Therefore, the production cost and production profit will be higher than that of ordinary drugs. ”

"Isn't it an extract of the human placenta?" asked the white man behind Hawthorne.

"It's not. Yang Rui replied simply. As a rare disease, Gaucher disease has been studied a lot in the medical community, which is one of the reasons why Yang Rui chose it. If there is no research of more than 20 years of predecessors, you have to do basic research by yourself, which is not a simple job, especially the requirements of modern medicine, it must be a quantitative result, and it is difficult to be recognized to give a plan or direction for granted, and quantitative often means long-term experiments, which is not easy.

In the early days of Gaucher disease, enzyme replacement was the most natural way of thinking.

The structure of grape cerebrosidase in patients with Gaucher disease has changed, and it cannot play its due role, so it is better to supplement some normal grape cerebrosidease.

If the deficiency of enzymes is common, this solution can be regarded as a preliminary solution to Gaucher disease. Unfortunately, the early medical experts who studied Gaucher disease were not able to find an easy source of supply of grape cerebrosidelase.

In fact, most of the compounds synthesized by the human body are difficult to have a stable supply, such as the insulin needed by diabetics, which has also gone through many generations of research to have a cheap, stable and large supply.

There is no ready-made supply of grape cerebrosidase, so it can only be searched from the human body, and in the end, only the human placenta is a very reluctant source of supply, it is a discarded thing after all, although there are many troubles in collecting and using it, it is always a life-saving thing.

However, it is conceivable that the cost of grape cerebrosidase is extremely high when this method of extraction is used, and very few Gaucher patients can be treated.

Yang Rui's alternative is to prepare an analogue of grape cerebrosidase in the ovarian cells of Chinese hamsters through DNA recombination technology, although it cannot completely cure Gaucher disease, but the use of a bi-weekly regimen can greatly prolong the life of patients and reduce pain.

For the hundreds of thousands of people who suffer from Gaucher disease, as well as those with related genetic mutations that will continue to appear in the future, this is the voice of heaven.

"Is there any other way to extract it without using human placenta extracts?" is there a protocol?" asked the GramSmithKline guy.

Yang Rui smiled, and refused to say anything more when he said that DNA recombinant technology, and he did not need to explain the plan for developing drugs to several representatives of pharmaceutical companies, but his confidence and the aura of the Nobel Prize shrouded the entire laboratory.

"In principle, we are willing to participate in joint ventures. "It's still GramSmithKline's people who speak first.

"We're going to think about it. Hawthorne's voice was a little muffled. Greenstone Corner had not thought of a joint venture before.

Leander hesitated for a moment, and could only say regretfully: "Let's quit." ”

With only a small sales and production department, and they rely on the purchase of various formulas to survive, they do not have the ability and ambition to engage in cross-border joint ventures.

Yang Rui expressed satisfaction, from his point of view, as long as he can say that a foreign company can be moved, it means that the plan is effective, and then make a plan based on it, as for how to achieve it, it is the work of Secretary Hu and his office.

What Yang Rui really cares about is DNA recombination technology. Although in another ten or twenty years, recombinant DNA has been played by various laboratories, but in the time when the human genome project has not been completed or even really launched, recombinant DNA is still very high-end.

Being able to realize and advance into practice is a good thing for the ion channel laboratory, which is both famous and wealthy.

……

(End of chapter)